[6-K] TRINITY BIOTECH PLC Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Trinity Biotech plc reports that interest due for May 2026 under its credit agreement with Perceptive Credit Holdings III, LP will be capitalised and added to the outstanding principal. Perceptive has also granted a limited waiver related to Section 8.15 of the credit agreement for June 2026.

Insights

Credit and capital structure analyst

Capitalised interest and a limited covenant waiver point to tighter credit flexibility.

Trinity Biotech and lender Perceptive Credit Holdings III, LP agreed to capitalise the May 2026 interest, adding it to the principal under the existing credit agreement. This defers a cash interest payment but increases the company’s debt balance.

Perceptive also granted a limited waiver concerning Section 8.15 of the credit agreement for June 2026. A waiver of a specific provision typically indicates the company may have been close to, or in, non-compliance with that covenant, and required lender accommodation.

The filing highlights ongoing reliance on this credit facility and the lender’s willingness to adjust terms. Future company disclosures will be important to understand whether these changes are one-off accommodations or part of a broader restructuring of Trinity Biotech’s capital structure.

Key Terms

capitalised, principal balance, credit agreement, limited waiver, +1 more

5 terms

capitalised financial

"the interest payable under the Company’s credit agreement ... will be capitalised and added to the principal balance"

principal balance financial

"interest payable under the Company’s credit agreement ... will be capitalised and added to the principal balance outstanding"

Principal balance is the remaining amount of money still owed on a loan or debt instrument, not including interest or fees. For investors, it determines the size of upcoming cash flows, the amount that must be repaid if the borrower pays off the debt early, and the exposure to default—think of it as the unpaid 'purchase price' of a loan that drives interest income and repayment risk. Understanding principal balance helps investors value bonds, loans, and securitized assets and assess potential returns and losses.

credit agreement financial

"interest payable under the Company’s credit agreement with Perceptive for May 2026 will be capitalised"

A credit agreement is a written loan contract between a borrower and a bank or other lender that lays out how much money can be borrowed, the interest rate, repayment schedule, fees, and the rules the borrower must follow. For investors, it matters because those terms affect a company’s cash costs, borrowing flexibility and risk of default — similar to how a mortgage’s rules determine a homeowner’s monthly budget and freedom to make changes.

limited waiver financial

"Perceptive has also agreed to a limited wavier in respect of Section 8.15 of the credit agreement"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391).

EXPLANATORY NOTE

The Company has agreed with its lender, Perceptive Credit Holdings III, LP (“Perceptive”), that the interest payable under the Company’s credit agreement with Perceptive for May 2026 will be capitalised and added to the principal balance outstanding, and Perceptive has also agreed to a limited wavier in respect of Section 8.15 of the credit agreement for June 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ Paul Murphy
		Paul Murphy
		Interim Chief Financial Officer

Date: June 5, 2026